Please assess the completion status of the following clinical trial:

Trial Title: Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who met the DSM-IV criteria for a primary diagnosis of ADHD of any subtype (may have been newly diagnosed with ADHD and not on treatment)~* score of 24 or higher on the ADHD Rating Scale (ADHD-RS) at screening~* physician must have rated the patient as Moderately ill or worse on the CGI-S at screening~* children may have been enrolled who were not receiving adequate treatment for ADHD (based on clinical judgment in consultation with the parent)~* children must have been washed-out of their current treatment a minimum of 3 days or 5 half lives of the medication whichever was longer~* and the child and parent must have given written informed consent, and assent, where applicable.~Exclusion Criteria:~* Female child who had experienced menarche~* presence of eating or substance disorder or co-morbid psychiatric condition other than oppositional defiant disorder~* history of seizure, tic disorder, mental retardation, severe developmental disorder (i.e. severe cerebral palsy, autism) or family history of Tourette's Disorder~* required medications as excluded by the package inserts for Concerta or Strattera~* diagnosed with hyperthyroidism or glaucoma~* and known non-responders to treatments indicated for ADHD.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).